Intraventricular injection of 8-Br-cADPR (5, 10, and 20 nmol) significantly prolonged convulsion latency (P = 0.037, 0.034, and 0.000, respectively), reduced convulsion duration (P = 0.005, 0.005, and 0.005, respectively), and reduced convulsion behavior scores (P = 0.015, 0.015, and 0.000, respectively).
Intraventricular injection was performed as previously described[sup] with slight modifications.
According to a previous pharmacological study, the maximum convulsive dose of ropivacaine is 33.8 mg/kg in rats.[sup] Therefore, 30 min after intraventricular injection, rats in the ropivacaine and ropivacaine+8-Br-cADPR groups were intraperitoneally injected with 33.8 mg/kg of 0.5% ropivacaine dissolved in 10 ml of normal saline solution.
Intraventricular injection of 8-Br-cyclic ADP-ribose reduces convulsion behavior scores, prolongs latency, and shortens duration of ropivacaine-induced convulsion
Intraventricular injection of 8-Br-cyclic ADP-ribose reduces electroencephalography spike waves
Intraventricular injection of 8-Br-cyclic ADP-ribose reduces CD38 and cyclic ADP-ribose levels following ropivacaine-induced convulsion
Intraventricular injection of 8-Br-cADPR (5, 10, and 20 nmol) significantly reduced intracellular cADPR levels compared to the ropivacaine group ( P = 0.026, 0.035, and 0.016, respectively).
Intraventricular injection of 8-Br-cyclic ADP-ribose inhibits apoptosis following ropivacaine-induced convulsion
The use of Adenoviral vectors (Ad-vectors) encoding GFP (Green Fluorescent Protein) or various other marker proteins, for example RFP (Red Fluorescent Protein), is very useful for many studies in the central nervous system including tract-tracing studies (1-2), intraventricular injections
(3) or ex vivo cell labelling for cell transplantation purposes.